[1]毕罡,毛成毅,江军,等.联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值[J].第三军医大学学报,2019,41(22):2195-2198.
 BI Gang,MAO Chengyi,JIANG Jun,et al.Expression of P504s and claudin-4 in prostate cancer and prognostic value of their combined detection[J].J Third Mil Med Univ,2019,41(22):2195-2198.
点击复制

联合检测P504s和Claudin-4在前列腺癌中的表达及其在预后评估中的价值(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第22期
页码:
2195-2198
栏目:
临床医学
出版日期:
2019-11-30

文章信息/Info

Title:
Expression of P504s and claudin-4 in prostate cancer and prognostic value of their combined detection
作者:
毕罡毛成毅江军张尧张军龙吟
陆军军医大学(第三军医大学)大坪医院:泌尿外科,病理科
Author(s):
BI Gang MAO Chengyi JIANG Jun ZHANG Yao ZHANG Jun LONG Yin
Department of Urology,Department of Pathology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042, China
 
关键词:
前列腺癌P504sClaudin-4组织芯片免疫组织化学预后
Keywords:
prostate cancer P504s claudin-4 tissue microarray immunohistochemistry prognosis
分类号:
R730.43;R730.7;R737.25
文献标志码:
A
摘要:

目的 通过联合检测α-甲酰基辅酶A消旋酶(P504s)和紧密连接蛋白-4(Claudin-4)在不同危险因素等级前列腺癌中的表达,探讨P504s和Claudin-4表达在前列腺癌预后评估中的价值。方法 选取我院病理组织库2013年1月至2015年7月的前列腺手术或穿刺标本共154例,按照病理诊断分为前列腺癌组84例,年龄52~83( 70.9±7.3) 岁;前列腺增生组70例,年龄51~85(68.2±7.4)岁。对2组标本组织采用组织芯片技术,构建组织芯片,S-P法检测P504s和Claudin-4蛋白的表达,并与前列腺癌预后进行相关性对比分析。结果 P504s和Claudin-4蛋白在前列腺增生组织中的阳性表达率明显低于前列腺癌组织(P<0.01)。P504s蛋白在不同Gleason评分前列腺癌组间阳性表达率没有明显差异;在不同分期前列腺癌组间的阳性表达率亦未见明显差异。而Claudin-4蛋白在前列腺癌Gleason评分≤6分和≥7分的阳性表达率分别为60.98%和74.42%,两者间比较差异有统计学意义 (P<0.05);在前列腺癌分期≤T2a期和≥T2b期的阳性表达率分别为55.26%和78.26%,两者间比较差异有统计学意义(P<0.01)。结论 P504s和Claudin-4蛋白的异常表达可能与前列腺癌的发生和进展相关,Claudin-4在危险等级越高的前列腺癌中的表达越高,联合检测可进一步提高前列腺癌的检出并对预后进行评估。

Abstract:

Objective To investigate the expression of P504s and claudin-4 in prostate cancer tissues and assess the value of their combined detection in prognostic evaluation of prostate cancer. MethodsWe analyzed a total of 154 surgical specimens or biopsy samples of prostate tissues collected between January, 2013 and July, 2015 in the pathological tissue bank of our hospital. These specimens, which consisted of 84 prostate cancer tissues from patients aged 52 to 83 years (mean 70.9±7.3 years) and 70 benign prostatic hyperplasia tissues from patients aged 51 to 85 years (mean 68.2±7.4 years), were used to construct 60-dot matrix paraffin tissue chips for detection of P504s and claudin-4 proteins using immunohistochemistry with SP method. The correlation of P504s and claudin-4 expression with the prognosis of the patients with prostate cancer was analyzed. ResultsThe positive expression rates of P504s and claudin-4 protein were significantly lower in benign prostatic hyperplasia tissues than in prostate cancer tissues (P<0.01). The tissue microarray data did not reveal significant difference in the positive expression rate of P504s in prostate cancer tissues with different Gleason scores or in different stages. The positive expression rates of claudin-4 protein was significantly lower in prostate cancer with a Gleason score ≤6 than in that with a score ≥7 (60.98% vs 74.42%, P<0.05), and was also lower in prostate cancer in T2a stage or lower than that in T2b stage or higher (55.26% vs 78.26%, P<0.01). ConclusionAbnormal expression of P504s and claudin-4 proteins may be related with the occurrence and progression of prostate cancer, and prostate cancer with a higher level of malignancy expresses higher levels of claudin-4. Combined detection of P504s and claudin-4 can improve the detection rate of prostate cancer and can be of value in prognostic evaluation of the patients.

参考文献/References:

[1]SHOU J F, ZHANG Q, WANG S, et al. The prognosis of different distant metastases pattern in prostate cancer:  A population based retrospective study[J]. Prostate, 2018, 78(7):  491-497. DOI: 10.1002/pros.23492. 
[2]杨进益, 杨明州, 魏伟, 等. 前列腺癌发生发展的流行病学研究进展[J]. 临床泌尿外科杂志, 2017, 32(9):  721-725. DOI: 10.13201/j.issn.1001-1420.2017.09.018.
YANG J Y, YANG M Z, WEI W, et al. Epidemiological study on the occurrence and development of prostate cancer[J]. J Clin Urol, 2017, 32(9): 721-725. DOI: 10.13201/j.issn.1001-1420.2017.09.018.
[3]STEPHAN C, JUNG K, SEMJONOW A, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:  ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer[J]. Clin Chem, 2013, 59(1):  280-288. DOI: 10.1373/clinchem.2012.195560.
[4]LAZZERI M, HAESE A, DELA TAILLE A, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml:  a multicentric European study[J]. Eur Urol, 2013, 63(6):  986-994. DOI: 10.1016/j.eururo.2013.01.011.
[5]REN S C, WANG F B, SHEN J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer[J]. Eur J Cancer, 2013, 49(13):  2949-2959. DOI: 10.1016/j.ejca.2013.04.026.
[6]FADARE O, ZHAO C Q, KHABELE D, et al. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma:  an immunohistochemical study of 279 ovarian tumours[J]. Pathology, 2015, 47(2):  105-111. DOI: 10.1097/PAT.0000000000000223.
[7]MARTNDELA FUENTE L, MALANDER S, HARTMAN L, et al. Claudin-4 expression is associated with survival in ovarian cancer but not with chemotherapy response[J]. Int J Gynecol Pathol, 2018, 37(2):  101-109. DOI: 10.1097/PGP.0000000000000394.
[8]CARTERH B, ALBERTSENP C, BARRYM J, et al. Early detection of prostate cancer:  AUA Guideline[J]. J Urol, 2013, 190(2):  419-426. DOI: 10.1016/j.juro.2013.04.119.
[9]JAIN D, GUPTA S, MARWAH N, et al. Evaluation of role of alpha-methyl acyl-coenzyme A racemase/P504S and high molecular weight cytokeratin in diagnosing prostatic lesions[J]. J Cancer Res Ther, 2017, 13(1):  21-25. DOI: 10.4103/0973-1482.206239.
[10]YEVGLEVSKIS M, LEEG L, SUN J, et al. A study on the AMACR catalysed elimination reaction and its application to inhibitor testing[J]. Org Biomol Chem, 2016, 14(2):  612-622. DOI: 10.1039/c5ob01541c.
[11]KAWANAMI T, TANAKA T, HAMAGUCHI Y,et al. Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation[J]. Endocrinology, 2018, 159(4):  1774-1792. DOI: 10.1210/en.2018-00099.
[12]CUIY F, LIUA H, AND Z,et al. Claudin-4 is required for vasculogenic mimicry formation in human breast cancer cells[J]. Oncotarget, 2015, 6(13):  11087-11097. DOI: 10.18632/oncotarget.3571.
[13]BHATA A, AHMAD R, UPPADAS B,et al. Claudin-1 promotes TNF-α-induced epithelial-mesenchymal transition and migration in colorectal adenocarcinoma cells[J]. Exp Cell Res, 2016, 349(1):  119-127. DOI: 10.1016/j.yexcr.2016.10.005.
[14]TOKUHARA Y, MORINISHI T, MATSUNAGA T,et al. Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues[J]. Oncol Lett, 2018, 15(1):  99-108. DOI: 10.3892/ol.2017.7281.
[15]ROMANOV V, WHYARDT C, WALTZERW C,et al. A claudin 3 and claudin 4-targeted Clostridiumperfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells[J]. Cancer Lett, 2014, 351(2):  260-264. DOI: 10.1016/j.canlet.2014.06.009.
 

更新日期/Last Update: 2019-11-21